Moscow – MD Medical Group Investments Plc, Russia’s leading provider of private women’s and children’s healthcare, announced the proposed acquisition of 100% of Vitanostra Ltd, operator of the IDK Medical Company network of women’s and children’s health clinics in the Russian region of Samara.
The sale is for a cash consideration of USD 16.1 mln for 100% of the outstanding share capital of Vitanostra Ltd, a parent company, which owns 100% of IDK Medical Company. The transaction is expected to be completed in the first half of 2013 after regulatory approvals.
Raiffeisen Investment acted as an exclusive sell-side financial advisor.
IDK Medical Company, one of the largest medical companies in Russia, is a network of women’s and children’s health clinics in the Russian region of Samara. Established in 1992 and recognised as the largest independent healthcare provider in the Samara region, IDK specializes in obstetrics (maternity), gynaecology, fertility treatment, paediatrics and clinical diagnostics.
IDK’s network includes two medical centres, a children’s polyclinic, a clinical diagnostics centre, two outpatient clinics in Tolyatti (Samara region’s second largest city) and
Novokuybyshevsk and two pharmacies, giving the group one of the strongest franchises in the region.
About Raiffeisen Investment
Raiffeisen Investment Russia, a 50:50 Joint Venture between Raiffeisenbank Russia and Raiffeisen Centrobank is a leading M&A advisor in Central Eastern Europe and Turkey. The guiding principle in our core fields of business Mergers&Acquisitions, Equity Capital Markets (ECM), Privatisations, Structured Transactions, Private Placements and Merchant Banking is to act in the best interests of our clients at all times. We do this by giving impartial advice and by combining top-level industry sector expertise of Raiffeisen Centrobank (Consumer Goods, Agro & Retail, Energy/Utilities, Financial Sponsors, Industrials, Life Sciences, Telecoms Media Technology) with local know-how through our Raiffeisen Investment network with more than 15 Country Offices. Our growing reputation and years of success mean that we have become the advisor of choice for transactions in emerging Europe.
